secwatch.observer — SEC 8-K summary
======================================

Issuer:     Adverum Biotechnologies, Inc. (—)
CIK:        0001501756
Form:       8-K
Filed at:   2023-08-04T23:59:59+00:00
Accession:  0001193125-23-203894
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Adverum appoints Linda Rubinstein as full-time CFO; $485K salary, 850K share option
--------------------------------------------------------------------------------

- Linda Rubinstein transitions from consulting CFO (via FLG Partners) to full-time CFO effective Aug 3, 2023.
- Base salary $485,000; target bonus 40%; option for 850,000 shares vesting over 36 months with 25% cliff at 6 months.
- Severance: 12 months salary plus equity vesting if termination near change in control; 9 months otherwise; reduced to 3 months in first year.
- Consulting agreement with FLG Partners terminated as of start date.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1501756/000119312523203894/0001193125-23-203894-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1501756/000119312523203894/d466076d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-203894

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer